This application is a proposal to serve as the Statistical and Data Management Center of the lnternational Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, as part of the IMPAACT Leadership Group (LG). The IMPAACT LG is proposing a research agenda for studies in pediatric and maternal populations to address objectives in the following NIAID high priority research areas: Vaccines of high priority to these populations;cure and/or functional cure of HIV;co-infections, co-morbidities and consequences of antiretroviral therapy;prevention of acquisition of HIV;pharmacology, drug formulate and novel interventions.
Our Specific Aims are: to support the international research agenda of the IMPAACT LG by providing a group of highly-experienced statisticians, epidemiologists, data managers and other professionals who are committed to collaborating with IMPAACT investigators;to provide expertise and high quality clinical and laboratory data management and communications systems to support the development, conduct and analysis of IMPAACT studies;and to advance the mission of the IMPAACT LG through innovation in study design and analysis, providing leadership in cross-study analyses, developing efficient methods and systems, and promoting harmonization with collaborating networks.

Public Health Relevance

The expertise provided by the SDMC will help advance research concerning the treatment and prevention of HIV and diseases such as tuberculosis and hepatitis in infants, children, adolescents, and pregnant women. It will achieve this by ensuring that IMPAACT clinical trials and other studies are efficiently designed and analyzed to the highest standards. This research will continue to make significant contributions in advancing optimal HIV treatment and prevention both in the United States and internationally.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-BP-A (S1))
Program Officer
Miller, Judith A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard University
Biostatistics & Other Math Sci
Schools of Public Health
United States
Zip Code
Mitchell, Charles D; Chernoff, Miriam C; Seage 3rd, George R et al. (2015) Predictors of resolution and persistence of renal laboratory abnormalities in pediatric HIV infection. Pediatr Nephrol 30:153-65
Fouda, Genevieve G; Cunningham, Coleen K; McFarland, Elizabeth J et al. (2015) Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. J Infect Dis 211:508-17
Rutstein, Richard M; Samson, Pearl; Fenton, Terry et al. (2015) Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J 34:162-7
Naranbhai, Vivek; Kim, Soyeon; Fletcher, Helen et al. (2014) The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life. BMC Med 12:120
Nachman, Sharon; Zheng, Nan; Acosta, Edward P et al. (2014) Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 58:413-22
Qin, Min; Brummel, Sean; Singh, Kumud K et al. (2014) Associations of host genetic variants on CD4? lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children. Pediatr Infect Dis J 33:946-52
Ciaranello, Andrea L; Leroy, Valeriane; Rusibamayila, Asinath et al. (2014) Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival. AIDS 28 Suppl 3:S287-99
Watts, D Heather; Stek, Alice; Best, Brookie M et al. (2014) Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr 67:375-81
Lindsey, Jane C; Hughes, Michael D; Violari, Avy et al. (2014) Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J 33:846-54
Clarke, Diana F; Acosta, Edward P; Rizk, Matthew L et al. (2014) Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr 67:310-5

Showing the most recent 10 out of 11 publications